View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

NUVISAN and ALS Limited Sign Strategic Partnership to Open New Markets

After a series of successful acquisitions, of which the recent takeover of a complete drug discovery unit in Berlin, NUVISAN enjoyed a very successful 2020. With more than 450 highly specialized scientists at NUVISAN´s Innovation Campus Berlin (ICB), in combination with the NUVISAN group employing 550 people across Europe at seven locations, the group generated overall sales of € 185 million (July1st 2020 to June 30th 2021) with a >20% EBITDA margin.

As a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO) the NUVISAN group offers integrated solutions along the full drug research and development value chain from target identification to Proof of Concept in patients in all supporting services. As the “Center of Excellence” for the ALS Life Sciences network, NUVISAN positions itself as a unique partner for Biotech, Venture Capital and Big Pharma clients.

Dr. Dietrich Bruchmann, owner and CEO of the NUVISAN group says “I am delighted we have found a strategic investor with ALS Limited whom we can achieve a real win-win situation. Our new partner from Australia gets access to new business areas and the European core markets. Thanks to the worldwide network of ALS Limited, our NUVISAN group has now the opportunity to win projects and customers in new markets such as the USA, Asia and Australia. This enables us to accelerate our growth towards our ambition to become one of the ´big players´ in our industry.”

Raj Naran, Managing Director and CEO of ALS Limited commented: “The investment in 49% of NUVISAN is a significant expansion of our Life Sciences capability as we grow our presence in strategically important pharmaceutical markets. This will allow us to move our service offering up the supply chain into drug development testing, which significantly expands our addressable markets. NUVISAN offers us a platform in the key markets of Germany and France which has long been an aspiration for our Life Sciences division. This is an important and highly strategic investment for us.”

The new, joint advisory board of the NUVISAN group will include the current management of NUVISAN and representatives of ALS Limited. The headquarters of the NUVISAN Group will remain in Neu-Ulm. NUVISAN will become the “Center of Excellence” for innovation and technology development for the entire ALS Life Sciences network.

The participation of ALS Limited supports the strong growth of the NUVISAN group, secures its highly specialized jobs in the long term and is the basis for further personnel growth.

In order to keep up with the latest developments in the field of cGMP regulated biopharmaceutical analytics, NUVISAN has added several Mass Spectrometry (MS) techniques...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena